Better AWR Outcomes. Reinforced by Data.

Five key studies demonstrate quality outcomes for **GORE® BIO-A® Tissue Reinforcement** in ventral hernia repair.*

**LOW complication rates in ventral hernia repair**

### LITERATURE SUMMARY
Follow-up 6–24 months | 382 patients, Gore devices
Study population includes high risk, complex patients

- **Seroma**: 6% [STUDY 1], 2% [STUDY 2], 1% [STUDY 3], 2% [STUDY 4], 0% [STUDY 5]
- **Bowel obstruction**: 0% [STUDY 1], 0% [STUDY 2], 0% [STUDY 3], 0% [STUDY 4], 0% [STUDY 5]
- **Hematoma**: 1–6% [STUDY 1], 18–24% [STUDY 2], 1% [STUDY 3], 6% [STUDY 4], 2% [STUDY 5]
- **SSI**: 2% [STUDY 1], 2% [STUDY 2], 1% [STUDY 3], 2% [STUDY 4], 0% [STUDY 5]
- **Fistula**: 2% [STUDY 1], 2% [STUDY 2], 2% [STUDY 3], 2% [STUDY 4], 0% [STUDY 5]
- **SSOs: wound complications / wound dihiscence**: 1–16.1% [STUDY 1], 18–24% [STUDY 2], 1% [STUDY 3], 6% [STUDY 4], 2% [STUDY 5]
- **Mesh removals**: ZERO complete mesh removals due to infection

### STUDY 1
Follow-up 24 months | 104 patients / Gore devices

- Seroma: 6%
- Bowel obstruction: 2%
- Hematoma: 1–6%
- SSI: 18–24%
- Fistula: 2%
- SSOs: wound complications / wound dihiscence: 18–24%
- Mesh removals: 0%

### STUDY 2
Follow-up 12 months | 94 patients / Gore devices

- Seroma: 0%
- Bowel obstruction: 0%
- Hematoma: 15.5%
- SSI: 0%
- Fistula: 0%
- SSOs: wound complications / wound dihiscence: 16.1%
- Mesh removals: 0%

### STUDY 3
Follow-up 9 months | 93 patients / Gore devices

- Seroma: 1%
- Bowel obstruction: 0%
- Hematoma: 6%
- SSI: 16.1%
- Fistula: 0%
- SSOs: wound complications / wound dihiscence: 2%
- Mesh removals: 0%

### STUDY 4
Follow-up 24 months | 99 patients / Gore devices

- Seroma: 2%
- Bowel obstruction: 2%
- Hematoma: 8%
- SSI: 0%
- Fistula: 0%
- SSOs: wound complications / wound dihiscence: 2%
- Mesh removals: 0%

### STUDY 5
Follow-up 6 months | 91 patients / Gore devices

- Seroma: 18%
- Bowel obstruction: 2%
- Hematoma: 24%
- SSI: 2%
- Fistula: 0%
- SSOs: wound complications / wound dihiscence: 0%
- Mesh removals: 0%

* Data on file 2018; W. L. Gore & Associates, Inc.; Flagstaff, AZ.
** Unrelated to mesh
10 YEARS EFFECTIVE CLINICAL USE

Complex and high-risk AWR cases
Hiatal / Paraesophageal hernia repair
Demonstrated economic value

• MORE than 150 publications
• LOW recurrence rates in hiatal hernias
• LOW recurrence rates in complex ventral hernias
• OVER 1700 patients in the clinical literature
• TARGETED absorption period avoids the risk for long-term mesh-related complications
• LOWER cost alternative to other non-permanent products